Literature DB >> 7750348

Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.

D A Waller1, G N Morritt, J Forty.   

Abstract

STUDY
OBJECTIVE: To evaluate the outcome of pleurectomy using video-assisted thoracic surgery (VATS) for pleurodesis in patients with malignant pleural effusion.
DESIGN: Cohort prospective study. Follow-up of patients from referral for thoracoscopy to death.
SETTING: Regional Cardiothoracic Surgical Centre. PATIENTS: Nineteen patients (median age 63 years, range 51 to 84 years) with malignant pleural effusion, secondary to mesothelioma in 13 and metastatic adenocarcinoma in 6. INTERVENTION: Video-assisted parietal pleurectomy. MEASUREMENTS AND
RESULTS: Median operating time was 35 min (range 15 to 60 min). The median fall in hemoglobin concentration in the first 24 h postsurgery was 1.1 g/dL (0.3-2.5 g/dL). The median postoperative morphine requirement was 1.25 mg/h (0-6.2 mg/h) in the first 12 h postoperatively. All patients were successfully extubated in the operating room, without the need for reventilation, and all patients were successfully discharged from the hospital with a median postoperative stay of 5 days (range 2 to 20 days). At current median follow-up of 12 months (range 4 to 17 mon) 6 patients died of their underlying disease. In the remaining 13 patients, two have developed recurrent effusions.
CONCLUSIONS: Using VATS to perform parietal pleurectomy is a safe, effective method of obtaining palliative pleurodesis in patients with malignant effusions.

Entities:  

Mesh:

Year:  1995        PMID: 7750348     DOI: 10.1378/chest.107.5.1454

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

Review 1.  Statement on malignant mesothelioma in the United Kingdom.

Authors: 
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

Review 2.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

3.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

4.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

5.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

Review 6.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 7.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

8.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

Review 9.  Management of malignant pleural mesothelioma-The European experience.

Authors:  Isabelle Opitz
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 10.  Pleural effusion.

Authors:  A R Medford; A Medford; N Maskell
Journal:  Postgrad Med J       Date:  2005-11       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.